Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Society for Immunotherapy of Cancer | Strategic Alliance Partners

      home / sap-partners / oncology-societies / sitc

      Latest from Society for Immunotherapy of Cancer


      doctor in white coat holding hand out with the word "immunotherapy" floating above

      Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

      Russ Conroy
      November 12th 2024

      Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.


      pancrease on a light blue background

      Mitazalimab Plus mFOLFIRINOX Improves Survival in Pancreatic Cancer

      Russ Conroy
      November 8th 2024

      Mitazalimab combined with mFOLFIRINOX led to responses and survival benefits in patients with metastatic pancreatic ductal adenocarcinoma.


      Society for Immunotherapy of Cancer Partners with Bonnie J. Addario Lung Cancer Foundation to Increase Participation in the Lung Cancer Registry

      Society for Immunotherapy of Cancer Partners with Bonnie J. Addario Lung Cancer Foundation to Increase Participation in the Lung Cancer Registry

      September 27th 2018

      The Society for Immunotherapy of Cancer (SITC) announced a new partnership to raise awareness of and participation in the Lung Cancer Registry, an initiative led by research and patient advocacy organizations, the Bonnie J. Addario Lung Cancer Foundation (ALCF), American Lung Association’s LUNG FORCE and the International Association for the Study of Lung Cancer.


      Oncology Nurses on the Frontlines of Immunotherapy Care

      Oncology Nurses on the Frontlines of Immunotherapy Care

      Society for Immunotherapy of Cancer
      September 7th 2016

      Cancer immunotherapies continue to show promising clinical outcomes, notably long-lasting remission, for an increasing number of malignancies.

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.